Physician profile
Ivan D Morris
NPI 1760757561
$14,212.90
in general payments reported to CMS, 2019-2025
75 companies · $2,095 in 2025
The $2,095 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,762 · 2020: $1,394 · 2021: $2,236 · 2022: $2,192 · 2023: $2,262 · 2024: $2,273 · 2025: $2,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,629.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,089.74 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,771.99 | 2019-2025 | |
| Amgen INC. | $1,469.50 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $1,407.44 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $896.35 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $787.65 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $418.02 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.55 | 2019-2025 | Jardiance, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $395.99 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $268.54 | 2023-2025 | Caplyta |
| Averitas Pharma INC. | $247.70 | 2023-2024 | Qutenza |
| Merck Sharp & Dohme LLC | $241.33 | 2019-2025 | Vaxelis, Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $239.33 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $227.39 | 2019-2023 | Airduo Digihaler |
| Amarin Pharma, INC. | $175.28 | 2020-2022 |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.